Genetic Signatures
Biotechnology ResearchNew South Wales, Australia51-200 Employees
Genetic Signatures is a global biotechnology company focused on molecular diagnostics, headquartered in Newtown, New South Wales, Australia. It specializes in syndromic multiplex real-time PCR testing to deliver configurable MDx solutions for infectious diseases, with its EasyScreen portfolio enabling detection of more than 100 pathogens. The EasyScreen kits rely on the company's 3base technology, which translates natural genetic sequences into A, T, and C to streamline multiplex assays and improve detection of pathogen subtypes and variants, including SARS-CoV-2. The company's products are accessible in over 30 countries, with direct representation in the United States, the United Kingdom, Germany, and Australia, and distribution partners in other regions for IVD use and research. Its customers are diagnostic laboratories and research settings seeking timely, accurate syndromic diagnosis and reliable workflows supported by high service standards and partnerships aimed at improving patient outcomes. In early 2026, Genetic Signatures announced an organizational overhaul designed to sharpen its commercial focus.